Supplemental Materials
SUPPLEMENTAL METHODS
Fingerprint chromatography of QL
Standard substances of aconitine, hydroxysafflor yellow A, ginsenoside Rg2, ginsenoside
Rb1, Astragaloside IV, ginsenoside Rd, acetytastragaloside 1, astragaloside II and ginsenoside
Rg3 were obtained from Chinese National Institute for the Control of Pharmaceutical and
Biological Products. Ten samples were randomly enrolled and disposed with the following
procedures for the HPLC analysis: 1.2 g samples resolved in 40 ml of 50% alcohol were
subjected to the ultrasound extraction for 30 min and then filtrated to collect filtrate. The
filtration was aqueous bathed until the alcohol was volatilized completely and then added by
water to 40 ml. The solution was diluted with 10% alcohol in the AB-8 macroporous
adsorptive resins to 160 ml, and then diluted with 80% alcohol to triplicate volume until the
eluant was achromatic. The eluant was concentrated and subjected to the analysis with HPLC.
HPLC for fingerprint analysis of QL extracts involved a water HPLC-PDA-evaprorative light
scattering detector (ELSD) and an agilent zorbax TC-C18 chromatographic column.
Separation was performed with gradient elution at a flow rate of 1.0ml/min and a column at
temperature of 30 °C.
To assess the dosing reproducibility of QL compounds, nine different batches were
randomly selected from all batches provided by Shijiazhuang Yiling Pharmaceutic and
subjected to HPLC to record fingerprint chromatograms of the QL extracts (Supplemental Fig.
1).
1
Supplemental Figure Legends
Fig. 1. High-performance liquid chromatography (HPLC) fingerprint chromatograms of QL
compounds. (A) HPLC fingerprint chromatogram of aqueous extract of QL compounds, with
the peaks for aconitine, hydroxysafflor yellow A, ginsenoside Rg2, ginsenoside Rb1,
astragaloside IV, ginsenoside Rd, acetytastragaloside 1, astragaloside II and ginsenoside Rg3,
respectively. (B) The similarity of nine samples detected by HPLC.
Fig. 2. Effects of different doses of QL on blood pressure (BP) of mice subjected to TAC.
Mice were administered with QL at the dose of 0.3, 0.6 or 1.2 mg/kg/day as indicated, and
subjected to sham or TAC operation for 2 (2W) or 4 weeks (4W). Aorta BP was measured by
use of a micronanometer catheter as described in Methods. Values are expressed as mean ±
S.E.M. of 6 mice (n=6). ** P < 0.01 vs. respective mice with Sham; # P < 0.05, vs. TAC mice
treated with Vehicle.
2